Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer

Acta Oncologica

Volumn 44, Issue 2, 2005, Pages 129-133

  Peters Engl, Christian ^a   Cassik, Pia ^a   Schmidt, Irene ^a   Denison, Ursula ^a   Medl, Michael ^a   Pokieser, Wolfgang ^a   Sevelda, Paul ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; HORMONE RECEPTOR; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TAXANE DERIVATIVE;

ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 17144429647     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510007530-1     Document Type: Article

References (25)

1. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 1993;16:22-5.
2. Bush RS, Jenkin RD, Alt WE, Beale FA, Bean H, Dernbo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37:302-6.
3. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiot Oncol Biol Phys 1986;12:2047-50.
4. Hong JH, Chen MS, Lin FJ, Tang SG. Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys 1992;222: 913-7.
5. Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G. The relationship of pre-treatment serum haemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 1998;83:726-31.
6. Bottini A, Berruti A, Brizzi MP, et al. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer 2003;89:977-82.
7. Obermair A, Cheuk R, Horwood K, et al. Impact of haemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer 2001;92:903-7.
8. Grogan M, Thomas GM, Melamed I, et al. The importance of haemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-36.
9. Höckel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993;51:141-9.
10. Vaupel P, Mayer A, Briest S, Höckel M. Oxygenation gain factor: a novel parameter characterizing the association between haemoglobin level and oxygenation status of breast cancers. Cancer Res 2003;63:7634-7.
11. Simpson-Herren L, Noker PE. Diversity of penetration of anti-cancer agents into solid tumours. Cell Prolif 1991;24: 355-65.
12. Teicher BA. Physiologic mechanisms of therapeutic resistance: blood flow and hypoxia. Hematol Oncol Clin North Am 1995;9:475-506.
13. Brown JM. Tumor hypoxia, drug resistance and metastases. J Natl Cancer Inst 1990;82:338-45.
14. Rockwell S. Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res 1997;9:383-90.
15. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
16. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-41.
17. Ardizzoni A, Venturini M, Sertoli MR, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br J Cancer 1994;69:385-91.
18. Denison U, Baumann J, Peters-Engl C, et al. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003;79:347-53.
19. Degner FL, Sutherland RM. Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic and experimental implications. Int J Radiat Oncol Biol Phys 1988;15:391-7.
20. Olsson AM, Svensson JH, Sundström J, et al. Erythropoietin treatment in metastatic breast cancer:effects on Hb, quality of life and need for transfusion. Acta Oncol 2002;41:517-24.
21. Larsson AM, Landberg G, Pahlman S, Albertsson M. Erythropoietin enhances response to treatment in patients with advanced breast cancer. Acta Oncol 2004;43:594-7.
22. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of Epoetin Alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo controlled trial. J Clin Oncol 2001;11: 2865-74.
23. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
24. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
25. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9.